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Summary: Up to now, members of the natriuretic peptide family have usually been determined by radioim-
munoassays using antibodies more or less specific for the distinct peptides so far identified. However, natriuretic
peptides differing significantly in their amino acid sequence from the one against which the antibody has been
raised cannot be determined by this means, and still unknown natriuretic peptides cannot be detected. We
therefore developed a new bioassay system sensitive to all members of the natriuretic peptide family by taking
advantage of the biological activity of these hormones, the activation of the guanylate cyclase/cyclic GMP
system. In this assay, cultured cells are incubated with the natriuretic peptides, and the amount of cyclic
GMP produced by the cells is determined by radioimmunoassay. From the relative stimulation of the cellular
cyclic GMP production, the concentration of natriuretic peptides in the sample is determined after calibration
with synthetic atrial natriuretic peptide. For a qualitative identification of the various peptides, the bioassay
is combined with a reversed-phase HPLC step. Using cultured bovine aortic endothelial or bovine kidney
epithelial cells for the bioassay, we achieved detection limits of 1 fmol or 50 fmol, respectively, for human
atrial as well as brain natriuretic peptide. Intra-assay coefficients of variation of 4.3% (aortic endothelial
cells, at 0.65 nmol/1 peptide) and 5.8% (kidney epithelial cells, at 6.5 nmol/1 peptide) were obtained. The total
content of natriuretic peptides as well as the amounts of the individual natriuretic peptides following HPLC
separation were determined in extracts of human atria obtained at aortocoronary bypass operations. Tissue
concentration values from 1.2 to 4.3 nmol peptide per gram wet weight were obtained, which corresponded
well with values determined by radioimmunoassays for human atrial and brain natriuretic peptide, thus
proving our method to be suitable for the detection of natriuretic peptides in biological samples.
Introduction . , . . . ,
 r _0 . . . .
atrial natriuretic peptide consists of 28 ammo acids
Natriuretic peptides form a family of hormones which (4, 5) which is derived from a 126-residue precursor
actively participate in the regulation of water and salt peptide (3) stored in dense secretory granules in the
balance in the mammalian organism. The potent and cardiac atrium. The peptide shows a variety of hu-
rapid natriuretic and diuretic effect of crude rat atrial moral actions resulting in a reduction of blood pres-
extract was first demonstrated by de Bo Id (1) in 1981, sure and blood volume (for review, see I.e. (6)). It
who thereby proved a humoral factor to be respon- interacts with the renin-angiotensin system by inhi-
sible for the stimulation of the kidney by volume bition of renin release, vasopressin release and aldo-
expansion sensed in the atrium of the heart. Subse- sterone synthesis and stimulates natriuresis and di-
quent purification led to the identification of atrial uresis. While these effects of atrial natriuretic peptide
natriuretic peptide (2, 3). The circulating form of are now relatively clear, receptors for the peptide are
found in various regions of the organism — for ex-
" ample in the small intestine, the ciliary body of the) This work was supported by the Robert-Bosch-Stiftung, 1 . 1 ^ 1 ^ Λ ^i ± ι
Stuttgart (Germany); and the Deutsche Forschungsgemein- eye, platelets, placenta, and the central nervous system
schaft (Ko 969/2-1) which is gratefully acknowledged. — where their function is not yet fully understood.
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Three different natriuretic peptides encoded by sep-
arate genes have been identified: atrial natriuretic
peptide, brain natriuretic peptide (7), and, most re-
cently, cardiac or C-type natriuretic peptide (8). Fur-
thermore, urodilatin, an N-terminally extended atrial
natriuretic peptide variant, which is thought to be
produced in the kidney, has been isolated from urine
(9). The atrial natriuretic peptide shows very high
amino acid sequence homology throughout different
mammalian species (10). The human, bovine and ca-
nine peptides are completely identical, and the mouse,
rat and rabbit peptides differ only in position 110,
which is isoleucine instead of methionine. Thus, most
atrial natriuretic peptides of different species can be
measured in a radioimmunoassay using the same an-
tibody (11). For the brain natriuretic peptide, how-
ever, marked interspecies sequence differences have
been found. Thus, using the antibody generated
against the porcine peptide (which was discovered
first), no cross-reacting peptide could be detected in
the human organism. A specific antibody against syn-
thetic human brain natriuretic peptide, based on the
putative amino acid sequence of this peptide, derived
from a cDNA, had to be designed, which delayed the
actual detection of the human peptide. As an alter-
native to the radioimmunoassay, a tedious physiolog-
ical assay system was also available, based on the
smooth muscle relaxing activity of the natriuretic pep-
tides (12). However, even in this assay system, signif-
icant differences between the activity of the various
natriuretic peptides were found (7).
Therefore, we designed a bioassay for the determi-
nation of all members of the natriuretic peptide fam-
ily, taking advantage of the common molecular mech-
anism of action of these peptides, i. e., the activation
of the guanylate cyclase-/cyclic GMP system (13). In
this report, we show that the bioassay yields reliable
and precise results which compare well with data
obtained by the classical radioimmunoassay methods.
Part of the data has been presented at the Annual
Meeting of the German Society for Clinical Chemis-
try, and has been published in abstract form (14).
Materials and Methods
Materials
Synthetic porcine brain natriuretic peptide, human atrial natri-
uretic peptide (99 — 126), and human brain natriuretic peptide
(77-108) as well as their 125I-labelled analogues, the antibodies
against all three peptides, normal rabbit serum and goat anti-
rabbit IgG were purchased from Peninsula Laboratories, Bel-
mont, CA (USA). In some cases, 125I-labelled porcine brain
natriuretic peptide and 125I-labelled human atrial natriuretic
peptide were also prepared in our laboratory according to the
lodogen method (15). Cyclic guanosine 3': 5'-monophosphate,
insulin and 3-isobutyl-l-methylxanthine were from Sigma, St.
Louis, MO (USA). The 125I-labelled tracer for the cyclic GMP
radioimmunoassay was prepared from (2'O-monosuccinyl-
guanosine 3': 5'cyclic monophosphate tyrosylmethylester,
Sigma) with 125I-sodium iodide (Amersham, Braunschweig,
Germany) using the chloramine T method. The rabbit anti-
cyclic GMP serum was a generous gift of Dr. F. Murad, Depts.
of Medicine and Pharmacology, Stanford University, Stanford,
CA (USA).
Dulbecco's modified Eagle's medium, pre-mixed Dulbecco's
modified Eagle's/Ham's F 12 medium, foetal calf serum, peni-
cillin/streptomycin and glutamine were purchased from Gibco
BRL/Life Technologies, Eggenstein (Germany). Tissue culture
dishes and bottles were from Falcon/Becton-Dickinson, Hei-
delberg (Germany), and Sep-Pak Qg-cartridges from Millipore/
Waters, Eschborn (Germany).
Bovine kidney epithelial cells (MDBK; CCL 22; frozen) were
obtained from American Type Culture Collection, Rockville,
MD (USA). A frozen stock culture of bovine aortic endothelial
cells, cloned originally from a primary culture (16), was kindly
provided by Dr. U. F rstermann, Cardiovascular Research Area,
Abbott Laboratories, Abbott Park, IL (USA).
Methods
Cell culture conditions
Bovine kidney epithelial cells were maintained in Dulbecco's
modified Eagle's Medium/corn's F12 (1 :1), 7.5 mmol/1
hydroxyethyl-piperazinyl-sulphonate (pH 7.4) containing 0.10
1/1 foetal calf serum, 25 kU/1 penicillin, 25 kU/1 streptomycin,
and 5 mg/1 insulin. Bovine aortic endothelial cells were cultured
in Dulbecco's modified Eagle's medium containing 0.101/1 foetal
calf serum, 2 mmol/1 glutamine, 25 kU/1 penicillin and 25 kU/1
streptomycin. Cells were maintained at 37 °C in 5% CO2 and
80% relative humidity.
Frozen cell stock suspensions (ca. 1—2 χ ΙΟ6 cells) were rapidly
thawed, washed twice with the respective serum-free culture
medium and dispensed into 25 cm2 culture flasks. The cells
usually became adherent within a day, their morphology was
checked daily and medium was changed every third day. After
7 to 10 days, when confluence was reached, the cells were
removed for passage by treatment with EDTA/trypsin (final
concentrations, 10 g/1 and 2.5 g/1, respectively) for 2—5 min,
washed twice, diluted 5-fold and dispensed into 150 cm2 flaks.
Multiwell plates were inoculated using the same procedure.
About 7 days later, these were used for the bioassays as de-
scribed below. Within a given batch of multiwell plates, the
cellular content of the wells varied by 10% at most.
Bioassay for determination of natriuretic peptides
Cells grown to confluence in 6-well (or 24-well) multiwell plates
were washed twice with 2 ml (1 ml) serum-free Dulbecco's mod-
ified Eagle's medium, 10 mmol/1 hydroxyethylpiperazinyl sul-
phonate (pH 7.3), and preincubated at 37 °C for 10 min with
990 μΐ Dulbecco's modified Eagle's medium containing 0.5
mmol/1 isobutylmethylxanthine. Ten microlitres of peptide so-
lution (in 1 g/1 bacitracin) were added and the cultures were
incubated for 5 min. The medium was aspirated, and 750 μΐ of
cold trichloroacetic acid (60 g/1) were added to the plates. The
cellular extracts were centrifuged for 20 min at 2000 g and the
supernatant extracted with water-saturated ether. Cyclic GMP
was determined by radioimmunoassay as described below.
Radioimmunoassay for cyclic GMP (17)
All samples, standards and tracer were diluted in 50 mmol/1
sodium acetate buffer, pH 4.0, to the desired concentration.
Sample or standard (50 μΐ) was added to 150 μΐ acetate buffer.
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After the addition of 100 μΐ cyclic GMP tracer and 100 μΐ
rabbit anti-cyclic GMP IgG (diluted ca. 10000 fold in the above
buffer with 0.1 g/1 bovine serum albumin), the tubes were
vortexed and incubated overnight at 4 °C. The immune com-
plexes formed were precipitated by adding 50 μΐ bovine γ-
globulin (1 g/1) and 2 ml cold 2-propanol. After centrifugation
for 30 min at 2000 g, the radioactivity of the pellet was deter-
mined in a model LB 2104 gamma counter (Berthold Labora-
tories, Wildbad, Germany).
Acetylation procedure for the cyclic GMP RIA
Sample or standard (500 μΐ) in 50 mmol/1 sodium acetate buffer
(pH 4.0) was pipetted into glass tubes, followed by 20 μΐ triethyl-
amine. The tubes were vigorously vortexed, 10 μΐ acetic anhy-
dride were added and the tubes were again vortexed. Only 2 — 3
samples should be treated at the same time. The acetylated
samples or standards may be stored for 2—3 days at 4 °C or
at -20 °C for several weeks.
Radioimmunoassay for human atrial, human brain, and porcine
brain natriuretic peptides
For the radioimmunoassays for all three peptides, we followed
the procedure recommended by the manufacturer (Peninsula
Laboratories). In brief, a two-day protocol with sequential
addition of 125I-labelled tracer and antibody was used; the
separation of bound and free radioactivity was achieved by
precipitation with goat anti-rabbit globulin.
Tissue extraction
Atrial appendices, which were routinely dissected for cannula-
tion of the vena cava during the extracorporeal circulation
procedure in cardiac operations, were placed into liquid nitro-
gen immediately after removal and stored at — 70 °C until use.
The frozen tissue was cut into small pieces which were boiled
in 0.1 mol/1 HC1 (1 ml/100 mg tissue, or at least 2ml) for 10
min to inactivate intrinsic proteases and then homogenized with
a Polytron mixer. The homogenates were centrifuged at 3000 g
for 60 min and the supernatant was diluted with 1 volume of
1 ml/1 trifluoroacetic acid and filtered. These tissue extracts
were loaded onto pre-conditioned Sep-Pak Q8 cartridges which
were then washed with 1 ml/1 trifluoroacetic acid. The peptides
were eluted with 2 ml 0.80 1/1 CH3CN containing 1 ml/1 trifluo-
roacetic acid. The eluates were dried in a vacuum centrifuge
(Speed-Vac, Savant, Farmingdale, NY, USA), stored at -20 °C
and dissolved in the appropriate buffer before use.
High-performance liquid chromatography analysis
A reversed-phase chromatography system on a Ci8 silica gel
column (Spherisorb ODS II, 3 μιη; 4.6 χ 125 mm; Bischoff,
Leonberg, Germany) was used with a binary solvent system:
solvent A, 1 ml/1 trifluoroacetic acid, 0.2 1/1 acetonitrile; solvent
B, l ml/1 trifluoroacetic acid, 0.6 1/1 acetonitrile. After injection
of the sample, a linear gradient from solvent A to solvent B in
15 min at an elution rate of 1 ml/min was applied, followed by
a plateau of 5 min solvent B before re-equilibration of the
column in solvent A. The absorbance of the eluate at 210 nm
was monitored using a Merck-Hitachi model 655 A variable
wavelength detector.
Results
Having previously tested several different types of
cultured cells for their suitability as a detection system
for natriuretic peptides, we finally concentrated our
work on two cell lines in which the cyclic GMP
production was already known to be stimulated by
atrial natriuretic peptide (13, 18), i.e., bovine kidney
epithelial cells and bovine aortic endothelial cells.
Following incubation of these adherent cells with
natriuretic peptides at increasing concentrations, the
intracellular concentration of cyclic GMP was deter-
mined.
Assay for natriuretic peptides using kidney
epithelial cells
As shown in figure 1, the cyclic GMP system of kidney
epithelial cells was equally sensitive to human atrial
and brain natriuretic peptides. The stimulation of the
cyclic GMP production started at a peptide concen-
tration of less than 0.10 nmol/1 of either human atrial
or human brain natriuretic peptide, and reached sat-
uration at about 100 nmol/1 peptide. The cellular
concentration of cyclic GMP increased from a basal
value of ca. l pmol/well to a maximum of ca. 12 — 15
pmol/well. The cultured kidney epithelial cells are
slightly less sensitive to porcine brain natriuretic pep-
tide (by a factor of 2; not shown).
The performance characteristics of the assay using the
cultured kidney epithelial cells are represented in table
1 showing a detection limit of 50 fmol human atrial
or brain natriuretic peptide and a variation coefficient
of 4.3% at an analyte concentration of 6.5 nmol/1
peptide (n = 15).
0 10 10'1 1 101 102
Peptide [nmol/l]
103 104
Fig. 1. Calibration curve for the bioassay for the determination
of natriuretic peptides using cultured bovine kidney
epithelial cells. After incubation of the cells with natri-
uretic peptides, the cellular cyclic GMP content was
determined by radioimmunoassay, as described in the
Methods section.
Closed circles: human atrial natriuretic peptide; open
circles; human brain natriuretic peptide. One well in the
multi-well dish contained ca. 5 χ ΙΟ6 cells. Each point
represents the mean result of a duplicate analysis.
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Tab. 1. Performance characteristics of the bioassay for the de-
termination of natriuretic peptides using the two dif-
ferent cultured cells lines. The stimulation of the cyclic
GMP production in bovine kidney epithelial or aortic
endothelial cells by the natriuretic peptides was deter-
mined as described under Methods, (n. d.: not deter-
mined)
Quantity
Range of stimulation
Maximal stimulation
Detection limit
rv^ v
 intra-assay
(n = 15); at
r*vv
-
/ Y
 inter-assay
(n = 8); at
Kidney
epithelial cells
0.1-100nmol/l
12-fold
50 fmol
4.3%
6.5 nmol/1
n.d.
Aortic
endothelial cells
0.001 -100 nmol/1
250-fold
1 fmol
5.8%
0.65 nmol/1
9.4%
0.65 nmol/1
Comparative studies in 6-well culture plates (9.1 cm2/
well) and 24-well plates (1.8 cm2/well) showed that
the sensitivity of the assay for natriuretic peptides was
significantly lower in 24-well plates (by a factor of
10) than in the larger wells. In the former wells, a
significant stimulation of the guanylate cyclase system
was observed only at concentrations of atrial natri-
uretic peptide exceeding 1 nmol/1.
Assay for natriuretic peptides using aortic
endothelial cells
Cyclic GMP production by cultured bovine aortic
endothelial cells was stimulated by concentrations of
human atrial or brain natriuretic peptide greater than
ca. 10~3 nmol/1. A maximal, 250-fold stimulation
occurred in response to a peptide concentration of ca.
100 nmol/1, which represented saturation (fig. 2).
These cells show both a lower basal cyclic GMP
concentration (ca. 0.2 pmol/well) and a higher maxi-
mal cellular cyclic GMP content following the stim-
ulation (ca. 50 pmol/well) than the kidney epithelial
cells. Thus, the dynamic range of the assay system
using the aortic endothelial cells is higher. A detection
limit of 1 fmol and an intra-assay variation coefficient
of 5.8% at a peptide concentration of 0.65 nmol/1
further demonstrate the higher sensitivity of the bioas-
say using these cells (tab. 1). The inter-assay coeffi-
cient of variation was 9.4% at 0.65 nmol/1 peptide.
Extrusion of cyclic GMP
Egress of cyclic GMP from the cytosol into the ex-
tracellular medium was monitored over a period of
120 minutes and found to be negligible during the
first 30 minutes. The concentration of cyclic GMP
accumulated in the medium within this period of time
did not exceed the extracellular basal value of ca. 90
fmol/well (fig. 3).
Combination of bioassay and high-perform-
ance liquid chromatography
For a qualitative identification of the individual na-
triuretic peptides, we coupled the bioassay with a
high-performance liquid chromatography step on a
reversed-phase silica gel column. Synthetic human
atrial natriuretic peptide, human brain natriuretic
100
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Fig. 2. Calibration curve for the bioassay for the determination
of natriuretic peptides (closed circles: human atrial na-
triuretic peptide; open circles: human brain natriuretic
peptide; asterisks: porcine brain natriuretic peptide) us-
ing cultured bovine aortic endothelial cells as described
in the Methods section. One well in the multi-well dish
contained ca. 4 χ ΙΟ5 cells.
Fig. 3. Time course of the egress of cyclic GMP from cultured
bovine kidney epithelial (open circles) and aortic en-
dothelial (closed circles) cells after stimulation with 10
nmol/1 human atrial natriuretic peptide. The cell dens-
ities per well were 5 χ ΙΟ5 cells for the kidney epithelial
cells and 1 χ ΙΟ5 cells for the aortic endothelial cells.
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jeptide and porcine brain natriuretic peptide were
ipplied separately to the HPLC column and identified
n the eluate by their individual retention times as
nonitored by their UV absorbance at 210 nm. The
mman atrial natriuretic peptide, human brain natri-
iretic peptide and porcine brain natriuretic peptide
duted at ca. 12.9 ml, 10.3 ml, and 14.9 ml, respec-
ively, the values differing slightly from column to
iolumn.
V mixture of all three peptides was chromatographed,
he eluate was collected in fractions, and -these frac-
ions were subjected to the bioassay for natriuretic
leptides using cultured bovine aortic endothelial cells.
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Fig. 4. Elution profile of natriuretic peptides in the reversed-
phase high-performance liquid Chromatographie anal-
ysis. A mixture of synthetic human atrial natriuretic
peptide, human brain natriuretic peptide, and porcine
brain natriuretic peptide (400 pmol of each peptide) was
chromatographed on a C18-silica gel column, as de-
scribed under Methods.
a) Determination of total natriuretic peptides in the
fractionated eluate with the bioassay using bovine
aortic endothelial cells.
b) Determination of human atrial (·) and brain (o)
natriuretic peptide as well as porcine brain natriuretic
peptide (*) by the respective radioimmunoassays.
Figure 4a shows the resulting stimulation of the cel-
lular cyclic GMP production by the natriuretic pep-
tides contained in the various fractions of the elution
profile. The elution volumes of the three signal peaks
obtained by the bioassay corresponded closely to
those observed by simultaneous UV absorbance mon-
itoring (not shown).
In order to further verify the elution volumes with
another independent method, we investigated the
same high-performance liquid Chromatographie frac-
tions in separate radioimmunoassays for human
atrial, human brain, and porcine brain natriuretic
peptide. Figure 4b represents the elution profile with
the peptide concentration values determined by these
radioimmunoassays. The respective signals were ob-
served in the same fractions as those of the bioassay
and the resulting peaks corresponded to those of the
elution profile obtained using the bioassay, without
significant deviation.
Analysis of a human cardiac extract by the
high-performance liquid chromatography/
bioassay combination
The results of the bioassays performed with the frac-
tionated eluate of a HPLC separation of an extract
prepared from a human atrial biopsy are shown in
figure 5. At the retention times previously found for
the atrial as well as the brain natriuretic peptide,
separate peaks were clearly distinguishable. The max-
imum of the cellular cyclic GMP production was
0.8
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Fig. 5. Reversed-phase high-performance liquid Chromato-
graphie elution profile of natriuretic peptides from hu-
man cardiac tissue. Peptides were extracted from part
of the atrial appendix dissected during aortocoronary
bypass surgery as described in the Methods section. The
extract was chromatographed on a Ci8-silica gel column,
and the natriuretic peptides in the fractionated eluate
were detected with the bioassay using bovine aortic
endothelial cells, as described under Methods.
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observed at an elution volume of ca. 13 ml which
corresponds to that of the synthetic atrial peptide. A
smaller peak eluted at ca. 10.7 ml, the elution volume
for synthetic brain natriuretic peptide. However, mi-
nor amounts of guanylate cyclase-stimulating sub-
stances were also eluted from the column after the
atrial peptide.
Comparison of natriuretic peptide concen-
trations determined by bioassay with those
obtained by radioimmunoassay
In a first application of the bioassay to the analysis
of biological samples, we determined the content of
natriuretic peptides in extracts of human cardiac atria
routinely dissected in heart surgery procedures.
Amounts of total natriuretic peptide in these samples
between 1.2 and 4.3 nmol/g tissue (wet weight) were
found. In the same tissue samples, concentrations of
human atrial and brain natriuretic peptide were meas-
ured separately using specific radioimmunoassay s.
Comparison of the results obtained by the two dif-
ferent assay systems (tab. 2) shows that the total
natriuretic peptide concentration, expressed as the
sum of the tissue levels of atrial and brain natriuretic
peptides determined by radioimmunoassay, differs
only marginally from the values obtained by using
the bioassay (maximal deviation, 18%; mean, 7.4%).
The radioimmunoassay gave a mean natriuretic pep-
tide concentration of 3.0 nmol/g tissue, whereas 2.8
nmol/g were found with the bioassay using the cul-
tured bovine aortic endothelial cells.
When the bioassay was combined with HPLC, the
cumulative sum of the masses of the different peptides
(obtained from the calibration curve of the bioassay)
also compared well with the value obtained by the
Tab. 2. Total concentration of natriuretic peptides in human
cardiac atria obtained during open heart surgery. Con-
centrations were determined either by the bioassay us-
ing bovine aortic endothelial cells or by radioimmu-
noassays for human atrial or brain natriuretic peptide,
as described in the Methods section. Additionally, the
relative difference between the values obtained by the
two methods is given (100% = radioimmunoassay
values).
Patient
No.
P 8
P 9
P 12
P 13
P 23
Natriuretic
Bioassay
1.24
3.32
1.59
4.29
3.51
peptides (nmol/g)
Radioimmunoassay
sum atrial brain
1.52 1.48 0.039
3.70 3.64 0.060
1.66 1.66 0.001
4.44 4.40 0.042
3.43 3.39 0.036
Differ-
(%)
18
10
4
3
2
radioimmunoassay. The brain natriuretic peptide
peak contained 0.08 nmol/g tissue, and the atrial
natriuretic peptide peak contained 1.10 nmol/g tissue
(1.3 nmol/g as determined by radioimmunoassay; cf.
also tab. 2).
Discussion
When this work was started, it was not known
whether a human equivalent of the natriuretic peptide
isolated from porcine brain (7) existed. Using anti-
bodies against the porcine peptide and a 125I-labelled
porcine brain natriuretic peptide tracer, we were un-
able to detect any cross-reacting substance in human
plasma (unpublished observations). This indicated a
significant difference between the amino acid se-
quences of the porcine and the putative human brain
natriuretic peptide. Even though a cDNA for the
human peptide was cloned, antibodies against human
brain natriuretic peptide were not yet available.
The purpose of our study was to develop an assay
system sensitive to all kinds of natriuretic peptides
regardless of their origin and their individual amino
acid sequence. A possible approach was to take ad-
vantage of the biological activity of the hormone
family, since all known natriuretic peptides share the
same molecular mechanism of action via a receptor-
mediated process. These peptides activate the mem-
brane-bound form of the enzyme, guanylate cyclase,
which releases intracellular cyclic GMP (13, 18 — 23).
Apart from the heat-stable toxin of Escherichia coli
(24), natriuretic peptides are the only known com-
pounds to activate particulate guanylate cyclase;
therefore, the stimulation of this enzyme-receptor
complex is a specific signal for the presence of natri-
uretic peptides in samples of mammalian origin.
Besides the laborious smooth muscle-relaxing bioas-
say for natriuretic peptides (12), another method for
the determination of these peptides had been de-
scribed which is not based on an immunological prin-
ciple. Ballermann (25) used rat kidney glomerular
membrane preparations for a sensitive radioreceptor
assay. However, the vast majority of binding sites for
natriuretic peptides in kidney membranes are C-type
receptors (26) not coupled to particulate guanylate
cyclase, which means that natriuretic peptides may
differ in their binding characteristics to this receptor
(27), leading to different sensitivities of the assay for
various natriuretic peptides. Furthermore, the radio-
receptor assay may also detect biologically inactive
degradation products of atrial natriuretic peptide. Ad-
ditionally, the concentration of the receptor protein
itself in the assay seems to be of critical importance
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(25), and last but not least, the assay requires the
periodic sacrifice of experimental animals.
It is surprising that the various peptides investigated
in this study showed similar efficiencies in the stim-
ulation of the cyclic GMP system. Using amino- or
carboxyterminally truncated atrial natriuretic peptide
analogues (which are unphysiological), e. g., atriopep-
tins I, II, and III, Lehman & Murad (28) found
different EC50 values for the elevation of the cellular
concentration of cylic GMP in bovine aortic endo-
thelial cells. These cells were almost 1000 times less
sensitive to atriopeptin I (which lacks the last 3 carb-
oxyterminal amino acids) than to the physiological
human atrial natriuretic peptide. Thus, it may be
speculated that atrial and brain natriuretic peptides
are equally effective in controlling the regulatory func-
tions of endothelial cells in vivo.
In our study, we used two different cultured cell lines
for the development of a bioassay for the determi-
nation of natriuretic peptides. When comparing the
relative merits of the bovine kidney epthelial and
aortic endothelial cells, several aspects have to be
considered. While the cultured bovine kidney epithe-
lial cells are easy to handle and commercially avail-
able, the culture of the bovine aortic endothelial cells
is more difficult, requiring a thorough control of the
morphology of the cells. On the other hand, the cyclic
GMP system of the latter cells shows a much higher
sensitivity to both human atrial and brain natriuretic
peptides than that of the kidney epithelial cells. The
detection limit of the bioassay using the bovine aortic
endothelial cells was in the same order of magnitude
as that of the radioimmunoassays for atrial (0.3 fmol)
or brain (1 fmol) natriuretic peptide. However, the
low basal cellular concentrations of cyclic GMP in
the aortic endothelial cells can be reliably determined
by the radioimmunoassay only after acetylation of
the samples, as the cyclic GMP assay using non-
acetylated samples is not sensitive enough. This sam-
ple preparation step is not necessary with the kidney
epithelial cell assay. Thus, the assay using kidney
epithelial cells may be useful for screening purposes
in samples with relatively high concentrations of na-
triuretic peptides, while the aortic endothelial cell line
should be used whenever a high sensitivity is required.
Cyclic GMP was monitored in the surrounding me-
dium, because it was conceivable that significant
quantities of the cyclic nucleotide generated following
the stimulation of the membrane-bound guanylate
cyclase could be lost from the cells. This would de-
crease the sensitivity of the assay, because the medium
is aspirated off the cells before the determination of
cellular cyclic GMP. However, the extrusion process
seems to be too slow to interfere with the determi-
nation of the cellular cyclic GMP content. Compared
with the basal or natriuretic peptide-stimulated cel-
lular content of cyclic GMP, the amount released
during the first 3 minutes of incubation with the na-
triuretic peptides can be ignored. Similar results have
also been obtained by Harnet et al. (29) who showed
that the egress of cyclic GMP in bovine aortic en-
dothelial cells, following a stimulation of the synthesis
by 0.1 μιηοΐ/l atrial natriuretic peptide, is slow in
onset.
Since the activation of the guanylate cyclase/cyclic
GMP system is the common feature of all natriuretic
peptides (13, 18, 23), the bioassay using cultured cells
does not distinguish between different natriuretic pep-
tides in biological samples. As shown in this study,
cultured bovine kidney epithelial and aortic endo-
thelial cells are equally sensitive to both human atrial
and brain natriuretic peptide. At a given concentra-
tion, different peptides produce the same rise in the
concentration of intracellular cyclic GMP. Though it
is theoretically conceivable that other, not yet discov-
ered members of the natriuretic peptide family in man
or other species may lead to higher or lower cellular
cyclic GMP concentrations than atrial or brain na-
triuretic peptide, or that they may show different
efficiencies in the stimulation of the cyclic GMP sys-
tem, these differences are not sufficient for a definite
qualitative identification of these peptides. This iden-
tification is achieved by the addition of the "second
dimension" to our assay system, the Chromatographie
step. Our data show that the different natriuretic
peptides known so far are reliably recognized and
quantitatively determined by the combination of the
bioassay with the high-performance liquid chroma-
tography separation, even in biological samples.
The data obtained with human cardiac atria using the
specific radioimmunoassays for human atrial and
brain natriuretic peptides confirm the results of the
bioassay for all natriuretic peptides investigated. The
absolute concentrations of natriuretic peptides deter-
mined in this study were in the same order of mag-
nitude as those reported by others. However, we
found somewhat lower concentrations of atrial as well
as brain natriuretic peptides in the atria of our patients
than Mukoyama et al. (30). The mean atrial tissue
levels of atrial and brain natriuretic peptides in their
report were 9.6 nmol/g, and 250 pmol/g, respectively.
In contrast to these authors who investigated heart
tissue obtained at autopsies, we used only small pieces
of atrial appendages obtained during cardiac surgery.
Regional differences in the tissue distribution may
account for the lower natriuretic peptide concentra-
tions reported by us.
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Compared with the specific radioimmunoassays for
the respective natriuretic peptides, the advantage of
the bioassay presented in this report is that it detects
all members of the natriuretic peptide family. How-
ever, the versatility of this method also constitutes its
disadvantage, in that the specific identification of a
particular natriuretic peptide requires the high-per-
formance liquid chromatography separation step. As
a consequence, the procedure becomes somewhat
lengthy and more laborious. However, for the analysis
of tissues or other biological samples where it has
been established previously that only one member of
the natriuretic peptide family is present, fractionation
by high-performance liquid chromatography should
not be necessary. This approach could also be adopted
for the determination of a particular member of the
natriuretic peptide family which is present in great
excess over the other natriuretic peptides in the sample
to be analysed.
In conclusion, we have shown that the bioassay using
cultured bovine kidney epithelial or aortic endothelial
cells with or without the reversed-phase high-perform-
ance liquid chromatography step represents a method
which is well suited for the quantitative and qualita-
tive analysis of natriuretic peptides in biological sam-
ples. However, the assay, especially in combination
with the Chromatographie procedure, is not intended
for a routine clinical diagnostic use but rather for
special investigations or research purposes.
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